KCT0001431Completed未知
A Randomized, Open-label, Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg and Immediate Release Formulation After Multiple Dosing Under Fasted Condition in Healthy Male Subjects
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Ildong pharmaceutical
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional Study
Eligibility Criteria
- Ages
- 20(Year) to 45(Year) (—)
- Sex
- Male
Inclusion Criteria
- •20~45 aged healthy adult.
- •someone tho has at least 50kg body weight and ideal body weight ±20%
Exclusion Criteria
- •someone has acute symptom at screening phase
- •someone has any disease or symptoms which is clinically significant
- •someone had been determined during healthy examination in screening period
- •AST or ALT > 1.5 times than normal
- •Total bilirubin > 1.5 times than normal
- •someone who has a history of allergy, anaphylaxis, drug abuse or misuse.
- •someone who had enrolled to other clinical trial within the last 60 days.
- •someone who had donated blood within the last 60 days.
- •someone who can't take a meal derived from this trial.
- •someone who has taken abnormal meals like which can affect to drug Absorbtion, Distribution, Metabolism, Excretion
- •someone who has taken other prescription medicine or oriental drugs within the last 14 days, Or over-the-counter drugs within the last 7 days
- •someone who has taken caffein continuously (coffee or green tea more than 5 cups per a day) or took caffein since 24hours before.
- •someone who has taken alcohol more than 30g/day or smoked more than 10 piece of tobacco/day.
- •someone who has galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
Investigators
Similar Trials
Completed
Not Applicable
A Crossover Clinical Trial to Compare The Pharmacokinetics of A GLA5PR GLARS-NF1 tablet 150mg and Immediate Release Formulation After Multiple Dosing under Fed Condition in Healthy Male SubjectsEndocrine, nutritional and metabolic diseaseKCT0001338GL PharmTech24
Active, not recruiting
Phase 4
Evaluation of the Implantation of an Anticoagulation Clinic in the Assistance of Chagas and Non-Chagas Patients at the Hospital of Clinics of the Universidade Federal de Minas Gerais - UFMGC03.752.300.900.200Heart DiseasesChagas DiseaseHemorrhageThrombosisD03.438.150.446.520.914C14.907.355C14.280.067.198C23.550.414RBR-88btzpniversidade Federal de Minas Gerais
Active, not recruiting
Not Applicable
Antiproteinuric effect of three different types of diuretics in patients with chronic proteinuric nephrophaties.Chronic proteinuric nephropathiesEUCTR2011-001929-24-ESFundación para la Investigación Biomédica del Hospital 12 de Octubre
Active, not recruiting
Not Applicable
Optimizing treatment of maldigestion in patients with chronic pancreatitisEUCTR2015-002570-20-ESDepartment of gastroenterology. University Hospital of Santiago
Completed
Not Applicable
Clinical trial to investigate pharmacokinetics and drug interaction of Crestor and Glucodown OR SR in healthy volunteersEndocrine, nutritional and metabolic diseaseKCT0000349Yuhan36